PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients with Left Ventricular Dysfunction Post STEMI

Circulation Research

Volumn 120, Issue 2, 2017, Pages 324-331

  Quyyumi, Arshed A ^a   Vasquez, Alejandro ^c   Kereiakes, Dean J ^d   Klapholz, Marc ^e   Schaer, Gary L ^f   Abdel Latif, Ahmed ^g   Frohwein, Stephen ^h   Henry, Timothy D ⁱ   Schatz, Richard A ^j   DIb, Nabil ^k   Toma, Catalin ^l   Davidson, Charles J ^m   Barsness, Gregory W ⁿ   Shavelle, David M ^o   Cohen, Martin ^p   Poole, Joseph ^a,b   Moss, Thomas ^q   Hyde, Pamela ^q   Kanakaraj, Anna Maria ^q   Druker, Vitaly ^q   Chung, Amy ^q   Junge, Candice ^q   Preti, Robert A ^q,r   Smith, Robin L ^q   Mazzo, David J ^q   Pecora, Andrew ^q   Losordo, Douglas W ^q   more..

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Athens Regional Medical Center   (United States)

^c HUNTSVILLE HOSPITAL   (United States)

^d CHRIST HOSPITAL   (United States)

^e RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF KENTUCKY   (United States)

^h Emory St Joseph's Hospital ^*  (United States)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

^j SCRIPPS HEALTH   (United States)

^k Heart Sciences Center   (United States)

^l UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^m NORTHWESTERN MEMORIAL HOSPITAL   (United States)

ⁿ MAYO CLINIC   (United States)

^o UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^p WESTCHESTER MEDICAL CENTER   (United States)

^q Caladrius Biosciences   (United States)

^r A Caladrius Company   (United States)

more..

Author keywords

cell transplantation; clinical trial; endothelial progenitor cells; heart failure; myocardial infarction

Indexed keywords

CD34 ANTIGEN; PLACEBO;

ADULT; ARTICLE; BIOLOGICAL ACTIVITY; CARDIOVASCULAR DISEASE; CELL THERAPY; CONTROLLED STUDY; CORONARY STENT; CORONARY STENTING; DOUBLE BLIND PROCEDURE; FEMALE; HEART DISEASE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE PERFUSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY ANALYSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; T LYMPHOCYTE; THERAPY EFFECT; AGED; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; COMPLICATION; CORONARY BLOOD VESSEL; DIAGNOSTIC IMAGING; DRUG EFFECTS; ETIOLOGY; HEART LEFT VENTRICLE FUNCTION; INTRAARTERIAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PROCEDURES; ST ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

AGED; ANTIGENS, CD34; BONE MARROW TRANSPLANTATION; CORONARY VESSELS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED; ST ELEVATION MYOCARDIAL INFARCTION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84995466868     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.308165     Document Type: Article

References (40)

1. Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Wang D, Pocock S, Pfeffer MA; Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005;112:3738-3744. doi: 10.1161/CIRCULATIONAHA.105.561423.
2. Mozaffarian D, Benjamin EJ, Go AS, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation. 2015;131:e29-e322. doi: 10.1161/CIR.0000000000000152.
3. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81:1161-1172.
4. Pfeffer MA. Left ventricular remodeling after acute myocardial infarction. Annu Rev Med. 1995;46:455-466. doi: 10.1146/annurev.med.46.1.455.
5. Hirai T, Fujita M, Nakajima H, Asanoi H, Yamanishi K, Ohno A, Sasayama S. Importance of collateral circulation for prevention of left ventricular aneurysm formation in acute myocardial infarction. Circulation. 1989;79:791-796.
6. Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation. 2000;102:IV14-IV23.
7. Sheiban I, Fragasso G, Rosano GM, Dharmadhikari A, Tzifos V, Pagnotta P, Chierchia SL, Trevi G. Time course and determinants of left ventricular function recovery after primary angioplasty in patients with acute myocardial infarction. J Am Coll Cardiol. 2001;38:464-471.
8. Ren G, Michael LH, Entman ML, Frangogiannis NG. Morphological characteristics of the microvasculature in healing myocardial infarcts. J Histochem Cytochem. 2002;50:71-79.
9. Niccoli G, Scalone G, Lerman A, Crea F. Coronary microvascular obstruction in acute myocardial infarction. Eur Heart J. 2016;37:1024-1033. doi: 10.1093/eurheartj/ehv484.
10. Massa M, Rosti V, Ferrario M, Campanelli R, Ramajoli I, Rosso R, De Ferrari GM, Ferlini M, Goffredo L, Bertoletti A, Klersy C, Pecci A, Moratti R, Tavazzi L. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood. 2005;105:199-206. doi: 10.1182/blood-2004-05-1831.
11. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353:999-1007. doi: 10.1056/NEJMoa043814.
12. Patel RS, Li Q, Ghasemzadeh N, et al. Circulating CD34+ progenitor cells and risk of mortality in a population with coronary artery disease. Circ Res. 2015;116:289-297. doi: 10.1161/CIRCRESAHA.116.304187.
13. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-967.
14. Mackie AR, Losordo DW. CD34-positive stem cells: in the treatment of heart and vascular disease in human beings. Tex Heart Inst J. 2011;38:474-485.
15. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood. 2000;95:952-958.
16. Sahoo S, Klychko E, Thorne T, Misener S, Schultz KM, Millay M, Ito A, Liu T, Kamide C, Agrawal H, Perlman H, Qin G, Kishore R, Losordo DW. Exosomes from human CD34(+) stem cells mediate their proangiogenic paracrine activity. Circ Res. 2011;109:724-728. doi: 10.1161/CIRCRESAHA.111.253286.
17. Steg PG, James SK, Atar D, et al; Task Force on the management of STsegment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569-2619. doi: 10.1093/eurheartj/ehs215.
18. Gerber Y, Weston SA, Berardi C, McNallan SM, Jiang R, Redfield MM, Roger VL. Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study. Am J Epidemiol. 2013;178:1272-1280. doi: 10.1093/aje/kwt109.
19. Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur A, Watt SM. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J. 2008;29:1807-1818. doi: 10.1093/eurheartj/ehn220.
20. Huikuri HV, Kervinen K, Niemelä M, Ylitalo K, Säily M, Koistinen P, Savolainen ER, Ukkonen H, Pietilä M, Airaksinen JK, Knuuti J, Mäkikallio TH; FINCELL Investigators. Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. Eur Heart J. 2008;29:2723-2732. doi: 10.1093/eurheartj/ehn436.
21. Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM; REPAIR-AMI Investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355:1210-1221. doi: 10.1056/NEJMoa060186.
22. Gyöngyösi M, Wojakowski W, Lemarchand P, et al; ACCRUE Investigators. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res. 2015;116:1346-1360. doi: 10.1161/CIRCRESAHA.116.304346.
23. Jeevanantham V, Butler M, Saad A, Abdel-Latif A, Zuba-Surma EK, Dawn B. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation. 2012;126:551-568. doi: 10.1161/CIRCULATIONAHA.111.086074.
24. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498-1504. doi: 10.1016/S0140-6736(96)07492-2.
25. Rosenzweig A. Cardiac cell therapy-mixed results from mixed cells. N Engl J Med. 2006;355:1274-1277. doi: 10.1056/NEJMe068172.
26. Li S, Zhou B, Han ZC. Therapeutic neovascularization by transplantation of mobilized peripheral blood mononuclear cells for limb ischemia. A comparison between CD34+ and CD34-mononuclear cells. Thromb Haemost. 2006;95:301-311. doi: 10.1160/TH05-06-0442.
27. Kawamoto A, Iwasaki H, Kusano K, Murayama T, Oyamada A, Silver M, Hulbert C, Gavin M, Hanley A, Ma H, Kearney M, Zak V, Asahara T, Losordo DW. CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. Circulation. 2006;114:2163-2169. doi: 10.1161/CIRCULATIONAHA.106.644518.
28. Quyyumi AA, Waller EK, Murrow J, et al. CD34(+) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. Am Heart J. 2011;161:98-105. doi: 10.1016/j.ahj.2010.09.025.
29. Sherwood M, Hage FG, Heo J, Shaw LJ, Cerqueira MD, Iskandrian AE. SPECT myocardial perfusion imaging as an endpoint. J Nucl Cardiol. 2012;19:891-894. doi: 10.1007/s12350-012-9583-0.
30. Abbate A, Bussani R, Biondi-Zoccai GG, et al. Infarct-related artery occlusion, tissue markers of ischaemia, and increased apoptosis in the peri-infarct viable myocardium. Eur Heart J. 2005;26:2039-2045. doi: 10.1093/eurheartj/ehi419.
31. Angeja BG, Gunda M, Murphy SA, Sobel BE, Rundle AC, Syed M, Asfour A, Borzak S, Gourlay SG, Barron HV, Gibbons RJ, Gibson CM. TIMI myocardial perfusion grade and ST segment resolution: association with infarct size as assessed by single photon emission computed tomography imaging. Circulation. 2002;105:282-285.
32. Brodie BR, Stuckey TD, Hansen CJ, Muncy DB, Weintraub RA, Kelly TA, Berry JJ. Timing and mechanism of death determined clinically after primary angioplasty for acute myocardial infarction. Am J Cardiol. 1997;79:1586-1591.
33. Busk M, Maeng M, Kristensen SD, Thuesen L, Krusell LR, Mortensen LS, Steinmetz ER, Nielsen TT, Andersen HR; DANAMI-2 Investigators. Timing, causes, and predictors of death after three years' follow-up in the Danish Multicenter Randomized Study of Fibrinolysis versus Primary Angioplasty in Acute Myocardial Infarction (DANAMI-2) trial. Am J Cardiol. 2009;104:210-215. doi: 10.1016/j.amjcard.2009.03.014.
34. Hofmann M, Wollert KC, Meyer GP, Menke A, Arseniev L, Hertenstein B, Ganser A, Knapp WH, Drexler H. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation. 2005;111:2198-2202. doi: 10.1161/01.CIR.0000163546.27639.A.A.
35. Vrtovec B, Poglajen G, Lezaic L, Sever M, Domanovic D, Cernelc P, Socan A, Schrepfer S, Torre-Amione G, Haddad F, Wu JC. Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ Res. 2013;112:165-173. doi: 10.1161/CIRCRESAHA.112.276519.
36. Lezaic L, Socan A, Poglajen G, Peitl PK, Sever M, Cukjati M, Cernelc P, Wu JC, Haddad F, Vrtovec B. Intracoronary transplantation of CD34(+) cells is associated with improved myocardial perfusion in patients with nonischemic dilated cardiomyopathy. J Card Fail. 2015;21:145-152. doi: 10.1016/j.cardfail.2014.11.005.
37. Losordo DW, Henry TD, Davidson C, et al; ACT34-CMI Investigators. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011;109:428-436. doi: 10.1161/CIRCRESAHA.111.245993.
38. Poglajen G, Sever M, Cukjati M, Cernelc P, Knezevic I, Zemljic G, Haddad F, Wu JC, Vrtovec B. Effects of transendocardial CD34+ cell transplantation in patients with ischemic cardiomyopathy. Circ Cardiovasc Interv. 2014;7:552-559. doi: 10.1161/CIRCINTERVENTIONS.114.001436.
39. Losordo DW, Kibbe MR, Mendelsohn F, et al; Autologous CD34+ Cell Therapy for Critical Limb Ischemia Investigators. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circ Cardiovasc Interv. 2012;5:821-830. doi: 10.1161/CIRCINTERVENTIONS.112.968321.
40. Vrtovec B, Poglajen G, Sever M, Lezaic L, Domanovic D, Cernelc P, Haddad F, Torre-Amione G. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. J Card Fail. 2011;17:272-281. doi: 10.1016/j.cardfail.2010.11.007.